A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
-
Cancer -
Multiple Myeloma
For the latest version of this information please go to www.forpatients.roche.com